Marshall Wace LLP Invests $390,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Marshall Wace LLP purchased a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 22,554 shares of the company's stock, valued at approximately $390,000. Marshall Wace LLP owned about 0.62% of LENZ Therapeutics at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LENZ. BNP Paribas Financial Markets acquired a new stake in shares of LENZ Therapeutics during the 1st quarter worth about $362,000. Jennison Associates LLC purchased a new position in shares of LENZ Therapeutics during the 1st quarter worth about $3,009,000. Marquette Asset Management LLC purchased a new position in shares of LENZ Therapeutics during the 1st quarter worth about $131,000. Vanguard Group Inc. purchased a new position in shares of LENZ Therapeutics during the 1st quarter worth about $4,621,000. Finally, American International Group Inc. purchased a new position in shares of LENZ Therapeutics during the 1st quarter worth about $44,000. 54.32% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Raymond James assumed coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They set an "outperform" rating and a $37.00 price objective on the stock. HC Wainwright assumed coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They set a "buy" rating and a $38.00 price objective on the stock. William Blair upgraded shares of LENZ Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Finally, Piper Sandler reiterated an "overweight" rating and set a $36.00 price objective on shares of LENZ Therapeutics in a report on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LENZ Therapeutics currently has an average rating of "Buy" and an average price target of $35.40.

LENZ Therapeutics Trading Up 4.7 %

NASDAQ LENZ traded up $1.11 during mid-day trading on Friday, hitting $24.71. The company's stock had a trading volume of 97,230 shares, compared to its average volume of 132,307. LENZ Therapeutics, Inc. has a 52-week low of $14.07 and a 52-week high of $29.82. The stock's fifty day simple moving average is $22.89 and its two-hundred day simple moving average is $20.10.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. On average, sell-side analysts predict that LENZ Therapeutics, Inc. will post -3.15 EPS for the current year.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.